Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q2- Text added to 2022 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
arrangement, BioNTech, characterized, decided, decompensation, Dusseldorf, EPO, equally, feedback, Germany, globe, GMT, infusion, IV, joint, jointly, Korea, MDE, meaningful, MHRA, objective, opposition, ornithine, OTC, pathway, Pfizer, preferred, reached, recurrent, repeated, restated, revert, revocation, revoke, SE, toxic, transcarbamylase, uninfected
Removed:
advancing, Allergy, Beta, boosting, broadly, case, competing, covered, delivered, Delta, demonstrated, divert, dosing, easier, elicit, expansion, facilitate, fall, final, focused, funded, goal, healthy, IAVI, key, leading, NaN, obtaining, personnel, portion, proceed, recent, Republic, retain, seropositive, solicited, test, trimer
Valuein 2022 Q2 filing- Value in 2022 Q3 filing
Original filings
Filing view